Myeloid-derived Suppressor Cells in Sepsis
The Roles of MDSCs (Myeloid-derived Suppressor Cells) in Adult Patients With Sepsis.
1 other identifier
observational
125
1 country
1
Brief Summary
This study is designed for septic patients, to isolate MDSCs and the correlation of prognosis of sepsis. The purpose of this study hopes to explore the phenomenon and possible mechanisms of MDSCs in patients with severe sepsis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2015
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2015
CompletedFirst Submitted
Initial submission to the registry
May 17, 2018
CompletedFirst Posted
Study publicly available on registry
May 30, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedMay 31, 2018
May 1, 2018
8.5 years
May 17, 2018
May 30, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Survival of Intensive care unit (ICU) stay
28 days
Secondary Outcomes (1)
In hospital survival
90 days
Study Arms (1)
Intensive care unit (ICU) patients with sepsis
Eligibility Criteria
The investigators will include patients admitted with diagnosis of sepsis in this study. Sepsis is defined by the consensus committee of American College of Chest Physicians and Society of Critical Care Medicine. The investigators will interview each patient and their family members, and review the medical records to obtain the baseline information including demographic data, clinical diagnosis, and evidence of dementia or psychiatric disorders. Acute physical and chronic health evaluation (APACHE II) score will be rated by chart review of data obtained within 24 hours of admission. The underlying medical history will also be collected.
You may qualify if:
- Patients must have known origin of infection .
- Systemic inflammatory response syndrome.
You may not qualify if:
- age less than 18 years
- pregnancy
- known anaphylactoid reaction to colloid fluids
- a life expectancy less than 24 hours,
- inability to provide informed, written consent
- Patients receiving nephrotoxic drugs,
- admitted to the hospital following a surgical procedure,
- sepsis more than 72 hours when screening .
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Chung Fu-Tsailead
Study Sites (1)
Chung Gung Memorial Hospital
Linkou District, 333, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Attending physician
Study Record Dates
First Submitted
May 17, 2018
First Posted
May 30, 2018
Study Start
July 1, 2015
Primary Completion
December 31, 2023
Study Completion
December 31, 2023
Last Updated
May 31, 2018
Record last verified: 2018-05
Data Sharing
- IPD Sharing
- Will not share